Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response

Trial Profile

Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Therapeutic Use
  • Acronyms Vaccimil
  • Most Recent Events

    • 01 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 08 Jan 2018 Results (n=93) assessing immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis, were published in the Rheumatology.
    • 29 Sep 2017 Planned End Date changed from 1 Nov 2015 to 31 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top